CSL Ltd (CSL) Stock Price, News & Insights | FP Markets Australia
Stay updated with the latest CSL Ltd (CSL) stock insights, price trends, and news. Explore CSL Share CFDs with FP Markets Australia
www.fpmarkets.comCSL has been under pressure with a sustained decline in its share price over the past year, with recent reports showing it trading at multi-year lows and a sizable year-to-date drop. The latest news indicates ongoing concerns about profitability guidance, margin pressures, and strategic changes (including any demerger plans and cost cuts) that have reduced investor confidence.
Key points from recent coverage:
What this means for investors:
Illustrative snapshot (as reported in recent coverage):
If you’d like, I can tailor a quick snapshot for your location (Miami, FL) with current ASX trading hours, or pull the most recent closing price and a short summary of the latest earnings/news to help you decide on any action. I can also create a simple chart showing the last 12–24 months of CSL prices if you want a visual sense of the decline.
Stay updated with the latest CSL Ltd (CSL) stock insights, price trends, and news. Explore CSL Share CFDs with FP Markets Australia
www.fpmarkets.comThe ASX closed lower as CSL plunged after a profit downgrade, while rising Middle East tensions pressured investor sentiment.
azzet.comCSL shares (ASX: CSL) extended a brutal 12-month selloff, briefly touching A$122.48 before closing higher at A$124.41 on Tuesday, with the price touching it's lowest price levels since 2017 and capping a 50% decline that has stunned long-term holders of what was once Australia's most reliable healthcare compounder. In a potentially interesting twist, the latest
thebull.com.auCSL shares (ASX: CSL) hit their lowest level since December 2017 on Monday, closing at A$142.22 after touching an intraday low of A$140.93, as markets continue to punish the biotech giant for a string of profit warnings, strategic missteps and abrupt leadership changes that have shattered its reputation as one of Australia's most dependable growth
thebull.com.auCSL shares (ASX:CSL) struck a fresh multi-year low at A$125.78, capping a 49.91% decline over twelve months as repeated guidance cuts and margin pressures continue to erode confidence in what was once Australia's most valuable healthcare stock. The CSL share price closed at their lowest level in nearly 10 years, extending a relentless stair-step decline
thebull.com.auCSL closed at about A$186.30 on Friday, 28 November 2025, with shares down roughly 34% for the year and market cap near A$90 billion.
ts2.techCSL, one of Australia's largest stocks by market value, plunged on resuming trade after two days on announcing a discounted $5 billion placement to fund the $11.7 billion acquisition of Swiss drugmaker Vifor Pharma.
economictimes.indiatimes.comCSL, one of Australia's largest stocks by market value, plunged on resuming trade after two days on announcing a discounted $5 billion placement to fund the $11.7 billion acquisition of Swiss drugmaker Vifor Pharma.
economictimes.indiatimes.com